DavidJohnDeBrotaMD

PubMed

• 2 citations
  Serum Lipid and Protein Changes in Healthy Dyslipidemic Subjects Given a Selective Inhibitor of p70 S6 Kinase-1
  Jennifer Leohr, Debra Luffer-Atlas, M. Jane Luo, David J. DeBrota, Colin F. Green, Thomas Edward Mabry, Jeffrey G. Suico> ;Journal of Clinical Pharmacology. 2018 Apr 1
• 22 citations
  Baseline Parameters in Clinical Trials for Nonalcoholic Steatohepatitis: Recommendations From the Liver Forum.
  Yuval A. Patel, Joanne C. Imperial, Andrew J. Muir, Quentin M. Anstee, David J. DeBrota, Lara Dimick-Santos, Claudia Filozof, Ruby Mehta, Arun J. Sanyal, Elmer Schabel...> ;Gastroenterology. 2017 Sep 1
• 24 citations
  Pharmacokinetics and pharmacodynamics of the cathepsin S inhibitor, LY3000328, in healthy subjects
  Christopher D. Payne, Mark A. Deeg, Melanie Chan, Lai Hock Tan, Elizabeth Smith Labell, Tong Shen, David J. DeBrota> ;British Journal of Clinical Pharmacology. 2014 Dec 1
• 52 citations
  Site versus centralized raters in a clinical depression trial: impact on patient selection and placebo response.
  Kenneth A. Kobak, Andrew F. Leuchter, David J. DeBrota, Nina Engelhardt, Janet B. W. Williams, Ian A. Cook, Andrew C. Leon, Jonathan E. Alpert> ;Journal of Clinical Psychopharmacology. 2010 Apr 1
• 24 citations
  Changes in brain function during administration of venlafaxine or placebo to normal subjects.
  Andrew F. Leuchter, Ian A. Cook, David J. DeBrota, Aimee M. Hunter, William Z. Potter, Caroline C. McGrouther, Melinda Morgan, Michelle Abrams, Barbara Siegman> ;Clinical EEG and Neuroscience. 2008 Oct 1
• 9 citations
  Optimizing the ability of the Hamilton Depression Rating Scale to discriminate across levels of severity and between antidepressants and placebos.
  Darcy A. Santor, David Debrota, Nina Engelhardt, Steve Gelwicks> ;Depression and Anxiety. 2008 Sep 1
• 24 citations
  Is it easier to find what you are looking for if you think you know what it looks like
  James C. Mundt, John H. Greist, James W. Jefferson, David J. Katzelnick, David J. DeBrota, Phillip B. Chappell, Jack G. Modell> ;Journal of Clinical Psychopharmacology. 2007 Apr 1
• 20 citations
  Anchoring perceptions of clinical change on accurate recollection of the past: memory enhanced retrospective evaluation of treatment (MERET).
  James C. Mundt, David J. DeBrota, John H. Greist> ;Psychiatry. 2007 Mar 1
• 17 citations
  An integrative approach to determine the best behavioral and biological markers of methylphenidate.
  Daniel F. Hermens, Nicholas J. Cooper, C. Richard Clark, David Debrota, Simon Clarke, Leanne M. Williams> ;Journal of Integrative Neuroscience. 2007 Mar 1
• 20 citations
  An Examination of 26,168 Hamilton Depression Rating Scale Scores Administered via Interactive Voice Response Across 17 Randomized Clinical Trials
  Heidi K. Moore, James C. Mundt, Jack G. Modell, Heidi E Rodrigues, David J. DeBrota, James J Jefferson, John H. Greist> ;Journal of Clinical Psychopharmacology. 2006 Jun 1
• 29 citations
  Rating the raters: assessing the quality of Hamilton rating scale for depression clinical interviews in two industry-sponsored clinical drug trials.
  Nina Engelhardt, Alan D. Feiger, Kenneth O. Cogger, Dawn Sikich, David J. DeBrota, Joshua D. Lipsitz, Kenneth A. Kobak, Kenneth R. Evans, William Z. Potter> ;Journal of Clinical Psychopharmacology. 2006 Feb 1
• 20 citations
  Neurophysiologic Correlates of Side Effects in Normal Subjects Randomized to Venlafaxine or Placebo
  Aimee M. Hunter, Andrew F. Leuchter, Melinda Morgan, Ian A. Cook, Michelle Abrams, Barbara Siegman, David J. DeBrota, William Z. Potter> ;Neuropsychopharmacology. 2005 Apr 1
• 32 citations
  The dose-dependent effect of methylphenidate on performance, cognition and psychophysiology.
  Nicholas J. Cooper, Hannah A.D. Keage, Daniel F. Hermens, Leanne M. Williams, David Debrota, C. Richard Clark, Evian Gordon> ;Journal of Integrative Neuroscience. 2005 Mar 1
• 48 citations
  An Item Response analysis of the Hamilton Depression Rating Scale using shared data from two pharmaceutical companies
  Kenneth R. Evans, Terrence Sills, David J. DeBrota, Steve Gelwicks, Nina Engelhardt, Darcy A. Santor> ;Journal of Psychiatric Research. 2004 May 1
• 161 citations
  Assessing and interpreting treatment effects in longitudinal clinical trials with missing data
  Craig H. Mallinckrodt, Todd M. Sanger, Sanjay Dubé, David J. DeBrota, Geert Molenberghs, Raymond J. Carroll, William Z. Potter, Gary D. Tollefson> ;Biological Psychiatry. 2003 Apr 15
• 11 citations
  Determination of pregnancy outcome risk rates after exposure to an intervention.
  David J. Goldstein, Karen L. Sundell, David J. DeBrota, Walter W. Offen> ;Clinical Pharmacology and Therapeutics. 2001 Jan 1
• 42 citations
  Study of the analgesic effect of lanepitant in patients with osteoarthritis pain.
  David J. Goldstein, Ouhong Wang, Lora E. Todd, Bruce D. Gitter, David J. DeBrota, Smriti Iyengar> ;Clinical Pharmacology and Therapeutics. 2000 Apr 1
• 44 citations
  The impact of restrictive entry criterion during the placebo lead-in period.
  R. Landin, David J. DeBrota, T. A. DeVries, William Z. Potter, Mark A. Demitrack> ;Biometrics. 2000 Mar 1
• 181 citations
  The responsiveness of the Hamilton Depression Rating Scale
  Douglas E. Faries, John Herrera, Jyoti Rayamajhi, David J. DeBrota, Mark A. Demitrack, William Z. Potter> ;Journal of Psychiatric Research. 2000 Jan 1
• 1 citations
  In front of us
  David J. DeBrota> ;International Journal of Bio-Medical Computing. 1994 Jan 1
• 60 citations
  THE PROBLEM OF MEASUREMENT ERROR IN MULTISITE CLINICAL TRIALS
  Mark A. Demitrack, Douglas E. Faries, J. M. Herrera, David J. DeBrota, William Z. Potter> ;Psychopharmacology Bulletin. 1998 Jan 1
• Man/microcomputer telephone communication.
  DeBrota, D.> ;MD Comput. 1986 Jul 01
• Blood gas consultant.
  DeBrota, D.> ;MD Comput. 1986 Mar 01
• Join now to see all